Drug Makers Outsourcing To China Exposed To Safety Issues
This article was originally published in PharmAsia News
Executive Summary
The move by multinational drug makers to outsource work to low-wage countries such as China is exposing the companies to the consequences of lax safety provisions. Safety issues in China already are causing concern in the U.S. FDA and in other countries that import its drugs. China is the world's largest producer of active pharmaceutical ingredients. The latest incident involves Baxter International and harmful side effects of its Heparin (heparin sodium), supplied by a Chinese company whose identity the FDA does not disclose. (Click here for more - a subscription may be required